American Journal of Obstetrics and Gynecology
ResearchGynecologyThree-year continuation of reversible contraception
Section snippets
Materials and Methods
In 2007, the Contraceptive CHOICE Project (CHOICE) began recruiting women for a prospective observational cohort study. The goal of the study was to reduce the unintended pregnancy rate in the St. Louis, MO, area by promoting the most effective methods of contraception and eliminating the cost barrier to all forms of contraception. The methods have been reported in detail16 but are described briefly below. The Human Research Protection Office at Washington University in St. Louis approved the
Results
Of 9256 CHOICE participants, the first 5090 were observed for 3 years. In this cohort, 382 women were excluded because they did not start their chosen baseline method by the 3-month survey. There were a total of 4708 participants (92%) who were observed for 3 years and were included in this analysis. A flow diagram of included participants is shown in Figure 1. There were 185 women (4%) who were censored because of discontinuation for desire to conceive or pregnancy.
Demographic and reproductive
Comment
Continuation rates for LARC methods at 1, 2, and 3 years are significantly higher than non-LARC methods. After adjustment for confounding variables, the choice of a shorter-acting method and younger age were associated with increased discontinuation.1, 4, 18, 19 Teens 14–19 years of age were more likely to discontinue than women of ≥20 years old. However, of those adolescents who chose LARC methods, more than one-half were still using their method at 3 years compared with one-fifth of
References (21)
- et al.
Intrauterine contraception with copper and with levonorgestrel: a randomized study of the TCu 380Ag and levonorgestrel 20 mcg/day devices
Contraception
(1984) - et al.
Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial
Contraception
(1994) - et al.
Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study
Contraception
(1990) - et al.
A three-year evaluation of TCu 380 Ag and multiload Cu 375 intrauterine devices
Contraception
(1988) - et al.
Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study
Contraception
(2003) - et al.
Continuation rates of Implanon in the UK: data from an observational study in a clinical setting
Contraception
(2006) - et al.
The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception
Am J Obstet Gynecol
(2010) - et al.
Structured contraceptive counseling provided by the Contraceptive CHOICE Project
Contraception
(2013) - et al.
Effectiveness of long-acting reversible contraception
N Engl J Med
(2012) - Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15 -44: United States, 2011 -2013. NCHS...
Cited by (0)
The Contraceptive CHOICE Project is funded by an anonymous foundation. This publication also was supported by Washington University Institute of Clinical and Translational Sciences grant number UL1 TR000448 from the National Center for Advancing Translational Sciences and award number K23HD070979 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.
J.F.P. receives research funding/support from Bayer, Teva, and Merck and serves on advisory boards for Teva Pharmaceuticals and MicroCHIPs; T.M. serves on an advisory board for Bayer Healthcare Pharmaceuticals and a data safety monitoring board for phase 4 safety studies of Bayer contraceptive products; the remaining authors report no conflict of interest.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Cite this article as: Diedrich JT, Zhao Q, Madden T, et al. Three-year continuation of reversible contraception. Am J Obstet Gynecol 2015;213:662.e1-8.